Breast cancer chemoprevention

Trials with tamoxifen have clearly shown that the risk of developing oestrogen receptor positive breast cancer can be reduced by at least 50% with prophylactic agents. The current challenge is to find new agents which achieve this or better efficacy, but with fewer side effects. Recent results indic...

Full description

Bibliographic Details
Main Authors: Ivana Sestak, Jack Cuzick
Format: Article
Language:English
Published: PAGEPress Publications 2011-12-01
Series:Oncology Reviews
Subjects:
Online Access:http://www.oncologyreviews.org/index.php/or/article/view/130